Clinical efficacy and tolerability of levofloxacin in patients with liver disease: A prospective, non comparative, observational study

Journal of Chemotherapy

Volumn 18, Issue 1, 2006, Pages 33-37

  Esposito, Silvano ^a   Noviello, S ^a   Leone, S ^a   Ianniello, F ^a   Ascione, T ^a   Gaeta, G B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bacterial infection; Levofloxacin; Liver diseases

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; LEVOFLOXACIN; SPIRONOLACTONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONVULSION; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HALLUCINATION; HUMAN; HYPOALBUMINEMIA; KIDNEY DYSFUNCTION; KLEBSIELLA; LABORATORY TEST; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; NAUSEA; NEUROTOXICITY; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PROTEUS; PROTHROMBIN TIME; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE COUNT; URINARY TRACT INFECTION;

EID: 33645109975     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.1.33     Document Type: Article

References (22)

1. Angeletti C, Piselli P, Bidoli E et al. Analysis of infectious disease mortality in Italy. Infez Med 2004; 12: 174-180.
2. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358.
3. Navasa M, Rimola A, Rodes J. Bacterial infections in liver disease. Semin Liver Dis 1997; 17: 323-333.
4. Westphal JF, Jehl F, Vetter D. Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. Clin Infect Dis 1994; 18: 324-335.
5. Russo M, Carmellino S. The choice of antibiotic therapy for bacterial infections in patients with cirrhosis of the liver. Infez Med 1997; 5: 87-95.
6. Toledo C, Salmeron JM, Rimola A et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251-257.
7. Rolachon A, Cordier L, Bacq Y et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22: 1171-1174.
8. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.
9. Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002; 62: 2127-2167.
10. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: A Therapeutic Review. Clin Ther 1998; 20: 1049-1070.
11. Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr Infect Dis Rep 2001; 3: 29-34.
12. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 (Suppl): 29-36.
13. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
14. th Edition, Churchill Livingstone Eds, 1995, 1153-1158.
15. Knodell R.G, Ishak KG, Black WC et al. Formulation and application of a numerical score system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1: 431-435.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard M2-A6. Villanova, Pennsylvania, 1997.
17. Borio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-48.
18. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10 (Suppl): 141-146.
19. Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 1990; 26 (Suppl): 61-67.
20. Preston SL, Drusano GL, Berman AI et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.
21. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-1597.
22. Sambatakou H, Giamarellos-Bourboulis EJ, Galanakis N, et al. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. Int J Antimicrob Agents 2001; 18: 441-444.